11:00 AM SIGN-IN & LUNCH • 11:30 AM - 1:00 PM
CE: Peanut Allergy and the Use of Immunotherapy for Specialty Pharmacists and Payers
The prevalence of peanut allergy has tripled in the past decade, and it is now estimated to affect as many as 1 million US children and adolescents. The management of this allergy is lifelong—just 20% of children are expected to outgrow their peanut allergy—and total direct medical costs per child with a peanut allergy are estimated to be more than $4 billion. With no known cure, accidental exposure to a peanut allergen and incidental anaphylactic reactions can be life-threatening for patients, and such emergencies result in higher health care expenditures. Clinical trials have sought to improve sensitivity thresholds for patients, and the recent approval of peanut oral immunotherapy presents an urgent need for specialty pharmacists and payers to understand the complexities of peanut allergy to effectively integrate this novel therapy into the current treatment paradigm. The crucial role of the specialty pharmacist’s involvement in dispensing treatments for patients with peanut allergy and managing and monitoring adverse effects of therapy will be discussed.